GEN Exclusives

More »

GEN News Highlights

More »
Oct 31, 2006

Dyax and ZymoGenetics Ink Library License Agreement

  • ZymoGenetics will use Dyax’ antibody phage display libraries to discover therapeutic antibodies according to a nonexclusive license.

    ZymoGenetics also received sublicenses to relevant third-party antibody phage display patents that may be used with Dyax’ antibody phage display technology. Under the terms of the agreement, Dyax will receive upfront and annual technology license fees, clinical milestone payments, and royalties on net sales of products that may result from this transaction.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?